These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35721667)

  • 1. Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia.
    Alex R; Gulam SM; Kumar K
    Adv Virol; 2022; 2022():7060466. PubMed ID: 35721667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia-A Retrospective Study.
    Chober D; Aksak-Wąs B; Niścigorska-Olsen J; Niekrasz M; Parczewski M
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.
    Altunal LN; Aydın M; Özel AS; Çam G
    Infect Dis Clin Microbiol; 2022 Jun; 4(2):116-121. PubMed ID: 38633336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study.
    Ibrahem HY; Aly DH; Warda AEA; Farahat RA; Youssef RM; Abdelhamid MH; Goud HA; Mohamed RR; Eldien MAYN; Alotaibi FO; Alzarea AI; Alanazi AS; Eisa NM; Refaee AS
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676678
    [No Abstract]   [Full Text] [Related]  

  • 6. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
    Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
    J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.
    Gao Q; Yin X; Tan B; Wang J; Chen J; Zhao B; Yang Q; Li Z
    BMC Infect Dis; 2022 Dec; 22(1):929. PubMed ID: 36503381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience of tocilizumab treatment among a cohort of patients with COVID-19 infection from Western India.
    Surana PD; Nayak R; Sheikh A; Haldankar P; Kale J
    J Family Med Prim Care; 2022 Jan; 11(1):123-132. PubMed ID: 35309657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.
    Li P; Lu Z; Li Q; Wang Z; Guo Y; Cai C; Wang S; Liu P; Su X; Huang Y; Dong Y; Qiu W; Ling Y; Yarmus L; Luo F; Zeng L; Bai C; Zhang W
    Front Mol Biosci; 2021; 8():651662. PubMed ID: 33937333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early use of tocilizumab in hospitalized patients with severe and critical COVID-19 in the Province of Buenos Aires: a multicentric study].
    Salazar M; Varela Baino AN; González S; González Martínez V; Varela T; Regairaz L; Torres K; Kreplak N; Estenssoro E
    Medicina (B Aires); 2023; 83(2):190-201. PubMed ID: 37094187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients.
    Wang Y; Chen Y; Zhou X
    Can J Infect Dis Med Microbiol; 2022; 2022():6375870. PubMed ID: 35308307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis.
    Petrelli F; Cherri S; Ghidini M; Perego G; Ghidini A; Zaniboni A
    World J Methodol; 2021 May; 11(3):95-109. PubMed ID: 34026583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study.
    Zarębska-Michaluk D; Jaroszewicz J; Rogalska M; Martonik D; Pabjan P; Berkan-Kawińska A; Bolewska B; Oczko-Grzesik B; Kozielewicz D; Tudrujek-Zdunek M; Kowalska J; Moniuszko-Malinowska A; Kłos K; Rorat M; Leszczyński P; Piekarska A; Polańska J; Flisiak R
    J Inflamm Res; 2021; 14():3359-3366. PubMed ID: 34295173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.
    Hassan M; Syed F; Zafar M; Iqbal M; Khan NU; Mushtaq HF; Badshah M
    Cureus; 2021 Dec; 13(12):e20219. PubMed ID: 35004038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.